The FDA on September 17, 2024, approved KEYTRUDA® with Pemetrexed and Platinum chemotherapy as first-line treatment of unresectable advanced or metastatic Malignant Pleural Mesothelioma (MPM). KEYTRUDA® is a product of Merck & Co., Inc.
Bottom Ad
Advertisement
Subscribe
